Melanoma

A phase 3 trial plans to further assess neoadjuvant darovasertib for the potential treatment of patients with primary uveal melanoma.

Tilsotolimod plus ipilimumab did not show benefit vs ipilimumab alone in anti–PD-1 refractory melanoma, despite prior positive phase 1/2 trial data.

Rodabe Amaria, MD, discusses the current role of OBX-115 for the treatment of patients with checkpoint inhibitor-resistant metastatic melanoma.

During a live event, James W. Smithy, MD, MHS, and other oncologists discussed how their experience with immune-related adverse events in metastatic melanoma has developed over time.

The anti–PD-1/VEGF combination of pembrolizumab and bevacizumab elicited strong clinical activity in patients with melanoma brain metastases.

Rodabe N. Amaria, MD, explains a trial of OBX-115, a novel engineered tumor infiltrating lymphocyte therapy, in checkpoint inhibitor-resistant metastatic melanoma.

Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib in stage III BRAF-mutated melanoma.

During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma with immunotherapy.

During a Case-Based Roundtable® event, Evan J. Lipson, MD, moderated a discussion on the tolerability of immunotherapy in metastatic melanoma and when to stop therapy.

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using combination immunotherapy for metastatic melanoma in the second article of a 2-part series.

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 affect their choice of therapy for metastatic melanoma in the first article of a 2-part series.

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the FDA with priority review.

Vusolimogene oderparepvec plus nivolumab showed responses and a favorable safety profile in advanced melanoma post-anti–PD-1 therapy, per phase 2 IGNYTE trial data.

In an interview, Vincent Law, of Moffitt Cancer Center, discussed a new study that offers hope for patients with melanoma brain metastasis.

The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 inhibitor–exposed melanoma.

Meredith McKean, MD, MPH, discussed findings from a longer-term follow-up study evaluating fianlimab plus cemiplimab for the treatment of metastatic melanoma.

During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the indirect comparison of ipilimumab plus nivolumab and nivolumab/relatlimab in advanced melanoma in the second article of a 2-part series.

TH17 cells may be a potential biomarker to predict the risk of immune-related adverse events in patients with metastatic melanoma receiving the combination therapy of nivolumab, ipilimumab, and tocilizumab.

During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the 2024 update to the RELATIVITY-047 trial in advanced melanoma in the first article of a 2-part series.

Fianlimab combined with cemiplimab demonstrated persistent and significant clinical activity in patients with advanced melanoma, regardless of LAG-3 or PD-L1 expression.

Atezolizumab following vemurafenib and cobimetinib shows improved overall survival in BRAF V600–positive melanoma, but not statistically significant.

Long-term findings from KEYNOTE-006, a phase 3 trial, support pembrolizumab as a standard-of-care for patients with advanced melanoma.

Nivolumab, alone or with ipilimumab, significantly improved 10-year overall and melanoma-specific survival vs ipilimumab alone in advanced melanoma, according to final phase 3 CheckMate 067 trial data.

RP1 with nivolumab treatment for patients with melanoma after progression on anti–PD-1 offers durable responses and a favorable safety profile, as shown in the IGNYTE study.

Meredith McKean, MD, discusses a longer-term follow-up study investigating fianlimab and cemiplimab immunotherapy in advanced melanoma.